Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, today confirms that following the Company’s financing announced on 18 October 2022, Dr. Eliot Forster, Non-Executive Chairman of the Company, subscribed for 15,000 ordinary shares of 10p each (“Ordinary Shares”) in the Placing at 95 pence per share.
Following his subscription, Dr. Eliot Forster owns 168,333 Ordinary Shares in the Company, representing 0.06% of the Company’s issued share capital.
Capitalised terms used but not otherwise defined in the text of this announcement shall have the meaning given to them in the Company’s announcements on the 18 October 2022.